First Time Loading...

Cytokinetics Inc
NASDAQ:CYTK

Watchlist Manager
Cytokinetics Inc Logo
Cytokinetics Inc
NASDAQ:CYTK
Watchlist
Price: 65.34 USD 0.83% Market Closed
Updated: Apr 27, 2024

Intrinsic Value

CYTK's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Cytokinetics, Inc. operates as a biopharmaceutical company. [ Read More ]

The intrinsic value of one CYTK stock under the Base Case scenario is 39.24 USD. Compared to the current market price of 65.34 USD, Cytokinetics Inc is Overvalued by 40%.

Key Points:
CYTK Intrinsic Value
Base Case
39.24 USD
Overvaluation 40%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Cytokinetics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CYTK stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Cytokinetics Inc

Provide an overview of the primary business activities
of Cytokinetics Inc.

What unique competitive advantages
does Cytokinetics Inc hold over its rivals?

What risks and challenges
does Cytokinetics Inc face in the near future?

Has there been any significant insider trading activity
in Cytokinetics Inc recently?

Summarize the latest earnings call
of Cytokinetics Inc.

What significant events have occurred
in Cytokinetics Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cytokinetics Inc.

Provide P/S
for Cytokinetics Inc.

Provide P/E
for Cytokinetics Inc.

Provide P/OCF
for Cytokinetics Inc.

Provide P/FCFE
for Cytokinetics Inc.

Provide P/B
for Cytokinetics Inc.

Provide EV/S
for Cytokinetics Inc.

Provide EV/GP
for Cytokinetics Inc.

Provide EV/EBITDA
for Cytokinetics Inc.

Provide EV/EBIT
for Cytokinetics Inc.

Provide EV/OCF
for Cytokinetics Inc.

Provide EV/FCFF
for Cytokinetics Inc.

Provide EV/IC
for Cytokinetics Inc.

Show me price targets
for Cytokinetics Inc made by professional analysts.

What are the Revenue projections
for Cytokinetics Inc?

How accurate were the past Revenue estimates
for Cytokinetics Inc?

What are the Net Income projections
for Cytokinetics Inc?

How accurate were the past Net Income estimates
for Cytokinetics Inc?

What are the EPS projections
for Cytokinetics Inc?

How accurate were the past EPS estimates
for Cytokinetics Inc?

What are the EBIT projections
for Cytokinetics Inc?

How accurate were the past EBIT estimates
for Cytokinetics Inc?

Compare the revenue forecasts
for Cytokinetics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cytokinetics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cytokinetics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cytokinetics Inc compared to its peers.

Compare the P/E ratios
of Cytokinetics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Cytokinetics Inc with its peers.

Analyze the financial leverage
of Cytokinetics Inc compared to its main competitors.

Show all profitability ratios
for Cytokinetics Inc.

Provide ROE
for Cytokinetics Inc.

Provide ROA
for Cytokinetics Inc.

Provide ROIC
for Cytokinetics Inc.

Provide ROCE
for Cytokinetics Inc.

Provide Gross Margin
for Cytokinetics Inc.

Provide Operating Margin
for Cytokinetics Inc.

Provide Net Margin
for Cytokinetics Inc.

Provide FCF Margin
for Cytokinetics Inc.

Show all solvency ratios
for Cytokinetics Inc.

Provide D/E Ratio
for Cytokinetics Inc.

Provide D/A Ratio
for Cytokinetics Inc.

Provide Interest Coverage Ratio
for Cytokinetics Inc.

Provide Altman Z-Score Ratio
for Cytokinetics Inc.

Provide Quick Ratio
for Cytokinetics Inc.

Provide Current Ratio
for Cytokinetics Inc.

Provide Cash Ratio
for Cytokinetics Inc.

What is the historical Revenue growth
over the last 5 years for Cytokinetics Inc?

What is the historical Net Income growth
over the last 5 years for Cytokinetics Inc?

What is the current Free Cash Flow
of Cytokinetics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cytokinetics Inc.

Financials

Balance Sheet Decomposition
Cytokinetics Inc

Current Assets 628.1m
Cash & Short-Term Investments 1.1B
Receivables 1.3m
Other Current Assets -489.9m
Non-Current Assets 196.3m
Long-Term Investments 40.5m
PP&E 147.7m
Other Non-Current Assets 8m
Current Liabilities 102.7m
Accounts Payable 85.7m
Accrued Liabilities 60.5m
Other Current Liabilities -43.5m
Non-Current Liabilities 1.1B
Long-Term Debt 607.4m
Other Non-Current Liabilities 500.6m
Efficiency

Earnings Waterfall
Cytokinetics Inc

Revenue
7.5m USD
Operating Expenses
-503.7m USD
Operating Income
-496.2m USD
Other Expenses
-30m USD
Net Income
-526.2m USD

Free Cash Flow Analysis
Cytokinetics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CYTK Profitability Score
Profitability Due Diligence

Cytokinetics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional ROE
Exceptional ROIC
ROE is Increasing
32/100
Profitability
Score

Cytokinetics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

CYTK Solvency Score
Solvency Due Diligence

Cytokinetics Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Negative Net Debt
Long-Term Solvency
43/100
Solvency
Score

Cytokinetics Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CYTK Price Targets Summary
Cytokinetics Inc

Wall Street analysts forecast CYTK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYTK is 96.96 USD with a low forecast of 60.6 USD and a high forecast of 128.1 USD.

Lowest
Price Target
60.6 USD
7% Downside
Average
Price Target
96.96 USD
48% Upside
Highest
Price Target
128.1 USD
96% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CYTK Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CYTK Price
Cytokinetics Inc

1M 1M
-9%
6M 6M
+106%
1Y 1Y
+73%
3Y 3Y
+144%
5Y 5Y
+595%
10Y 10Y
+1 365%
Annual Price Range
65.34
52w Low
26.88
52w High
108.06
Price Metrics
Average Annual Return 57.3%
Standard Deviation of Annual Returns 64.79%
Max Drawdown -44%
Shares Statistics
Market Capitalization 6.6B USD
Shares Outstanding 103 005 000
Percentage of Shares Shorted 20.7%

CYTK Return Decomposition
Main factors of price return

What is price return decomposition?

CYTK News

Other Videos

Last Important Events
Cytokinetics Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Cytokinetics Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Cytokinetics Inc Logo
Cytokinetics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

6.6B USD

Dividend Yield

0%

Description

Cytokinetics, Inc. operates as a biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 253 full-time employees. The company went IPO on 2004-04-29. The company is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF); CK-136, a cardiac troponin activator for the treatment of heart failure and other diseases; reldesemtiv (CK-2127107), a fast skeletal muscle troponin activator (FSTA) for the treatment of people living with debilitating diseases and conditions associated with muscular weakness; aficamten (CK-274), a cardiac myosin inhibitor designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy (HCM); and CK-3772271 (CK-271), a second novel cardiac myosin inhibitor.

Contact

CALIFORNIA
South San Francisco
350 Oyster Point Boulevard, .
+16506243000.0
http://cytokinetics.com/

IPO

2004-04-29

Employees

253

Officers

CEO, President & Director
Mr. Robert I. Blum
VP & Chief Accounting Officer
Mr. Robert C. Wong
Executive Vice President of Research & Development
Dr. Fady Ibraham Malik FACC, M.D., Ph.D.
Executive VP & Chief Commercial Officer
Mr. Andrew M. Callos
Co-Founder & Member of Scientific Advisory Board
Dr. James A. Spudich Ph.D.
Vice President of Sales & Operations
Mr. Jeff Lotz
Show More
Vice President of Corporate Finance and Financial Planning & Analysis
Mr. Matt Yang
Senior Vice President of Global Supply Chain Operations & Technical Operations
Mr. Steven M. Cook
Senior Vice President of Corporate Communications & Investor Relations
Ms. Diane Weiser
VP & Chief Compliance Officer
Ms. Kari K. Loeser J.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one CYTK stock?

The intrinsic value of one CYTK stock under the Base Case scenario is 39.24 USD.

Is CYTK stock undervalued or overvalued?

Compared to the current market price of 65.34 USD, Cytokinetics Inc is Overvalued by 40%.